Navigation Links
DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3)

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - Dyax Corp. (Nasdaq:DYAX) announced today positive topline results from its Phase 3, placebo-controlled trial, EDEMA3, for its lead product candidate DX-88 (ecallantide), for hereditary angioedema (HAE). A webcast presentation of the EDEMA3 data is scheduled for Tuesday, April 17, 2007 at 12:30 p.m. ET.

DX-88, an internally discovered, recombinant, plasma kallikrein inhibitor, is in clinical trials for the treatment of acute attacks of HAE, a rare genetic disease characterized by episodes of acute swelling and inflammation. Statistically significant results (DX-88-treated patients versus placebo) were achieved for both the primary and secondary endpoints in the EDEMA3 trial.

The primary endpoint, symptom improvement at four hours measured by a Treatment Outcome Score (TOS) developed for HAE attacks, had a p-value of 0.021. The two secondary endpoints also demonstrated statistical significance. The patient reported assessment of individual symptom burden at four hours measured using the Mean Symptom Complex Severity score (MSCS) had a p-value of 0.024. Time to significant improvement in overall response (defined for this trial as the first time post dosing that the patient reported the symptom complex as "a lot better" or "resolved" within the first 4 hours) had a median time of 149 minutes for the DX-88 group versus greater than 4 hours for the placebo group (p=0.044). The overall safety results showed that DX-88 continues to be well tolerated. There were no drug-related serious adverse events. EDEMA3 is the largest successfully completed, placebo-controlled trial for this indication under a United States Investigational New Drug application.

"We are extremely excited about the outcome of this EDEMA3 trial," commented Henry E. Blair, Chairman and Chief Executive Officer of Dyax. "Based on the topline results of this study, the extensive clinical dat
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
3. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
7. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
8. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
Post Your Comments:
(Date:7/10/2014)... , July 10, 2014  BC Technical, the largest ... MiE America , Inc., a leading provider of Siemens ... a long-term agreement naming BC Technical as the authorized ... MiE and BC Technical announced today that ... establish BC Technical as the service and systems provider ...
(Date:7/10/2014)... July 10, 2014 CVS Caremark Corporation (NYSE: ... has approved a quarterly dividend of $0.275 (27.5 cents) per ... on August 1, 2014, to holders of record on July ... CVS Caremark is dedicated to helping people on their path ... the United States . Through the company,s ...
(Date:1/15/2014)... 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced ... Global Industry Analysis, Size, Share, Growth, Trends And Forecast, ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) ... patients in order to treat dental impairments, for tooth ...
Breaking Medicine Technology:BC Technical Partners With MiE America To Be Authorized Provider Of Systems & Service 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3
... 25 BiPar Sciences, Inc., a,privately held ... molecular biomarker data demonstrating the overexpression,of the ... ovarian, breast and lung tumors. The research ... specific types of cancer. This,insight is being ...
... ... inhibitors, SAN FRANCISCO, ... the discovery, rapid,development and commercialization of therapies for solid tumors and,hematological ... the 2007 AACR-NCI-EORTC International Conference that,describe how its proprietary CLIMB technology ...
Cached Medicine Technology:BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types 2Data Support use of SuperGen's CLIMB Technology in Lead Development and Optimization 2Data Support use of SuperGen's CLIMB Technology in Lead Development and Optimization 3
(Date:7/11/2014)... Datalogic brings a new and innovative scanner ... With their new Gryphon GD4400 and GM4400 ... devastating MRSA, which claimed 5,500 lives, becomes more preventable. ... and the Gryphon GM4400-HC 2D readers can scan nearly ... barcodes off of troublesome LCD monitors, smartphones, and other ...
(Date:7/11/2014)... Boston, MA (PRWEB) July 11, 2014 ... save at least $50 billion in fuel ... effect immediately. The current GHG standards ... manufacturers have taken it upon themselves to ... they include: , 1.    Idle reduction technologies , ...
(Date:7/11/2014)... (HealthDay News) -- Children who have emergency surgery ... and potentially even death than those who have ... However, the Johns Hopkins researchers noted that the ... analyzed data on nearly 440,000 simple emergency surgeries ... a 22-year period. The surgeries are considered ...
(Date:7/11/2014)... Oakland, CA (PRWEB) July 11, 2014 Ticket ... tickets at the Concord Pavilion . When it comes to ... from Luke Bryan. The 37-year-old Georgia native is one of the ... in the entertainment business. Bryan is currently out on his “That’s ... Among the many stops the tour will be making through the ...
(Date:7/11/2014)... Alliance for Cancer Gene Therapy, ... exclusively to cell and gene therapies for cancer ... the organization as Senior Development Officer. , Corday ... securing gifts and addressing influential donors. Prior to ... for NewYork Presbyterian Hospital/Columbia University Medical Center, where ...
Breaking Medicine News(10 mins):Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3
... Bush,today visited the Maamobi Polyclinic in the Greater ... being implemented by AED to control,malaria., Through ... commercial,sector to increase the availability and affordability of ... and five,other sub-Saharan African countries, and is supported ...
... the recently,released Audit Bureau of Circulations FAS-FAX report, ... paid circulation in the,period from July 2007 through ... year. This increase was substantially larger than that ... Self, Shape, Health, Martha,Stewart Living and Natural Health., ...
... Provides Financial Guidance for 2008, BIRMINGHAM, Ala., Feb. 20 ... for its fourth quarter and,full year ended December 31, 2007., ... 14.7% decrease from,fourth quarter 2006 revenue of $33.5 million. The ... share. In the fourth quarter of 2006, the,Company earned net ...
... Patients with rheumatoid arthritis are twice as likely ... a doctor about it, according to researchers at the ... Rheumatoid arthritis (RA) the most common form of ... by inflammation of joint tissues, persistent pain, functional disability, ...
... Mouse study suggests it could help control diabetes in humans ... found a way to convert human embryonic stem (ES) cells ... ease a diabetes-like condition in mice, a new study says. ... lead to a renewable source of cells for treatment of ...
... in breast arteries upped chances of cardiovascular trouble, ... In addition to detecting breast cancer in its early ... predict which women are at risk for strokes. , ... -- what doctors call benign arterial calcifications -- were ...
Cached Medicine News:Health News:First Lady Laura Bush Visits AED/Netmark Malaria-Control Project in Ghana 2Health News:Yoga Journal Circulation Increases 5.8 Percent in Second Half of 2007 from Same Period Previous Year 2Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 2Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 3Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 4Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 5Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 6Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 7Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 8Health News:Emageon Reports Fourth Quarter and 2007 Financial Results 9Health News:Doctors should watch for depression in arthritis patients 2Health News:Researchers Make Stem Cells That Secrete Insulin 2Health News:Mammograms Might Spot Stroke Risk 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: